Despite methodological flaws that limit conclusions, a considerable database documents the efficacyof triiodothyronine (T3) as an augmentation strategy for response to various classes of antidepressants.One study suggests that T3 and lithium are of comparable efficacy in antidepressantnonresponders. No clear biochemical or clinical predictors of preferential response to T3 have beenfound. The role of T3 augmentation requires further evaluation, especially with regard to dose andduration
Enjoy free PDF downloads as part of your membership!
Save
Cite
Advertisement
GAM ID: sidebar-top